Programs
Search for
Sort by 
Page
Showing 1 - 25 of 34 documents.

Search for
Sort by 
Page
Showing 1 - 25 of 34 documents.
button
Previews
Featured programs
Poll
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.

How do you think the results of the MADIT-CRT trial (and other studies suggesting benefits of CRT device-based therapy in earlier-stage HF patients) will affect implant CRT rates in the next 3 years?
See: MADIT-CRT: Resynchronization therapy cuts heart-failure risk in patients with only mild disease
Rates will significantly increase (> 15% increase in primary prevention ICD utilization in congestive HF patients)
Rates will moderately increase (5%-10%)
Rates will slightly increase (2%-5%)
Rates will slightly increase (2%-5%)

Inside: Arrhythmia/EP
Arrhythmia/EP
Oct 21, 2009 11:32 EDT
Dr. Anne Curtis offers 2 cases of high-risk patients who present with shortness of breath. How are these patients diagnosed and treated?
Arrhythmia/EP
Oct 16, 2009 09:05 EDT
Rate control, rhythm control, new drugs and devices for anticoagulation -- the armamentarium of treatment options is expanding rapidly. Drs. Yancy, Cannon, and Boehmer discuss the latest treatment modalities for patients with AF.
Arrhythmia/EP
Sep 28, 2009 14:20 EDT
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.